Amin, Muhammad K and Boateng, Joshua ORCID: 0000-0002-6310-729X (2022) Surface functionalization of PLGA nanoparticles for potential oral vaccine delivery targeting intestinal immune cells. Colloids and Surfaces B: Biointerfaces, 222:113121. pp. 1-8. ISSN 0927-7765 (Print), 1873-4367 (Online) (doi:https://doi.org/10.1016/j.colsurfb.2022.113121)

Preview	PDF (Publisher VoR) 38368_BOATENG_Surface_functionalization_of_PLGA_nanoparticles_for_potential_oral_vaccine.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (530kB) | Preview
Preview	PDF (Publisher VoR) 38368_BOATENG_Surface_functionalization_of_PLGA_SUPPLEMENTAL MATERIAL.pdf - Supplemental Material Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (816kB) | Preview

Abstract

This study aimed to develop surface modified PLGA nanocarriers protecting protein-based antigen in the stomach to enable potential release of antigen at target intestinal sites. PLGA nanoparticles (NPs) were prepared by double emulsion and solvent evaporation techniques while surface functionalization was performed using polyethylene glycol (PEG), sodium alginate (ALG) and Eudragit L100 (EUD) with ovalbumin (OVA) as model protein antigen. Nanoparticles were characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), gel permeation chromatography (GPC), and stability in simulated gastric fluid (SGF)/simulated intestinal fluid (SIF). Structural integrity of released OVA was analyzed by circular dichroism (CD) and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), while cytotoxicity against Jurkat cells was determined using MTT assay. Surface functionalized PLGA NPs protected the protein in SGF and SIF better than the non-functionalized NPs. Average size of OVA encapsulated NPs was between 235-326 nm and were spherical. FTIR band change was observed after surface modification and showed sustained OVA release compared with the uncoated NPs. The secondary structure of OVA released after 96 hrs remained intact and MTT assay showed >80 % cell viability after 72 hrs while unmodified and surface modified NPs achieved 17 % and 48 % mucin binding respectively. In conclusion, surface modified PLGA NPs have been shown to be safe for potential oral protein-based vaccine delivery.

Item Type:	Article
Uncontrolled Keywords:	Eudragit; ovalbumin; PLGA nanoparticle; polyethylene glycol; mucosal vaccine; sodium alginate
Subjects:	Q Science > Q Science (General) R Medicine > R Medicine (General) R Medicine > RS Pharmacy and materia medica
Faculty / School / Research Centre / Research Group:	Faculty of Engineering & Science Faculty of Engineering & Science > School of Science (SCI)
Last Modified:	03 Jan 2023 10:09
URI:	http://gala.gre.ac.uk/id/eprint/38368

Actions (login required)

View Item

Downloads